

US007056913B2

(12) **United States Patent**
Kamal et al.

(10) **Patent No.:** **US 7,056,913 B2**
(45) **Date of Patent:** **Jun. 6, 2006**

(54) **C8—LINKED
PYRROLO[2,1-C][1,4]BENZODIAZEPINE-
ACRIDONE/ACRIDINE HYBRIDS**

(75) Inventors: **Ahmed Kamal**, Hyderabad (IN);
Srinivas Olepu, Hyderabad (IN);
Ramulu Poddutoori, Hyderabad (IN);
Ramesh Gujjar, Hyderabad (IN);
Praveen Kumar Pogula, Hyderabad
(IN)

(73) Assignee: **Council of Scientific and Industrial
Research**, New Delhi (IN)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 28 days.

(21) Appl. No.: **10/812,841**

(22) Filed: **Mar. 30, 2004**

(65) **Prior Publication Data**

US 2005/0222132 A1 Oct. 6, 2005

(51) **Int. Cl.**
C07D 401/12 (2006.01)
A61K 31/4375 (2006.01)
A61P 35/00 (2006.01)

(52) **U.S. Cl.** **514/220**; 540/496

(58) **Field of Classification Search** 540/496;
514/220

See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

EP	0 098 098	1/1984
WO	00 12508	3/2000

OTHER PUBLICATIONS

Kamal et al., Ahmed "Design, Synthesis, and Evaluation of
New Noncross-Linking Pyrrolobenzodiazepine Dimers with
Efficient DNA Binding Ability and Potent Antitumor Activ-
ity." J. Med. Chem.. (2002), 45, pp 4679-4688.

Thurston et al., David E. "Synthesis of Sequence-Selective
C8-Linked Pyrrolo[2,1-c][1,4]benzodiazepine DNA
Interstrand Cross-Linking Agents." J. Org. Chem. (1996),
61, pp. 8141-8147.

Schofield et al., Philip C. "Metabolism of N-[2-
(dimethylamino)ethyl]acridine-4-carboxamide in cancer
patients undergoing a phase I clinical trial." Cancer
Chemother Pharmacol (1999), 44, 51-58.

Gamage et al., Swarna A. "A New Synthesis of Substituted
Acridine-4-carboxylic Acids and the Anticancer Drug N-[2-
(Dimethylamino)ethyl]acridine-4-carboxamide (DACA)." *Tetrahedron Letters*, (1997), 38, 4, pp. 699-702.

Thurston et al., David E. "Synthesis of DNA-Interactive
Pyrrolo[2, 1-c][1,4]benzodiazepines." *Chem. Rev.* (1994),
94, pp. 433-465.

Primary Examiner—Bruck Kifle

(74) *Attorney, Agent, or Firm*—Ladas and Parry LLP

(57) **ABSTRACT**


The present invention provides novel pyrrolo-[2,1-c][1,4]
benzodiazepine hybrids useful as anti-tumour agents and a
process for the preparation thereof.

18 Claims, 1 Drawing Sheet

1
C8—LINKED
PYRROLO[2,1-C][1,4]BENZODIAZEPINE-
ACRIDONE/ACRIDINE HYBRIDS

FIELD OF THE INVENTION

The present invention provides novel pyrrolo-[2,1-c][1,4]benzodiazepine hybrids useful as anti-tumour agents. The present invention also provides a process for the preparation of new pyrrolo[2,1-c][1,4]benzodiazepine hybrids as antitumour agents. More particularly, the present invention provides a process for the preparation of 7-methoxy-8-[n'-(4"-acridonylcarboxyamido)alkyl]-oxy-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-methoxy-8-[n'-(4"-acridinylcarboxyamido)-alkyl]-oxo-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one with aliphatic chain length variation of these compounds and it also describes the DNA binding, anticancer (antitumour) activity. The structural formula of the novel pyrrolo[2,1-c]-[1,4]benzodiazepines of the invention is given below:




BACKGROUND OF THE INVENTION

Pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics are commonly known as anthramycin class of compounds. In the last few years, a growing interest has been shown in the development of new pyrrolo[2,1-c][1,4]benzodiazepines (PBDs). These antibiotics react covalently with DNA to form an N2-guanine adduct that lies within the minor groove of duplex DNA via an acid-labile aminal bond to the electrophilic imine at the N10-C11 position (Kunimoto, S.; Masuda, T.; Kanbayashi, N.; Hamada, M.; Naganawa, H.; Miyamoto, M.; Takeuchi, T.; and Unezawa, H. *J. Antibiot.*, 1980, 33, 665.; Kohn, K. W. and Speous, C. L. *J. Mol. Biol.*, 1970, 51, 551.; Hurley, L. H., Gairpla, C. and Zmijewski, M. *Biochem. Biophys. Acta*, 1977, 475, 521.; Kaplan, D. J. and Hurley, L. H. *Biochemistry*, 1981, 20, 7572). The molecules have a right-handed twist, which allows them to follow the

2

curvature of the minor groove of B-form double-stranded DNA spanning three base pairs. A recent development has been the linking of two PBD units through their C-8 positions to give bisfunctional alkylating agents capable of cross-linking DNA (Thurston, D. E.; Bose, D. S.; Thomson, A. S.; Howard, P. W.; Leoni, A.; Croker, S. J.; Jenkins, T. C.; Neidle, S. and Hurley, L. H. *J. Org. Chem.*, 1996, 61, 8141).



Recently, PBD dimers have been developed that comprises two C2-exo-methylene substituted DC-81 subunits tethered through their C-8 position via an inert propanedioxy linker (Gregson, S. J.; Howard, P. W.; Hartely, J. A.; Brooks, N. A.; Adams, L. J.; Jenkins, T. C.; Kelland, L. R. and Thurston, D. E. *J. Med. Chem.* 2001, 44, 737). Recently, a noncross-linking mixed imine-amide PBD dimers have been synthesized that have significant DNA binding ability and potent antitumour activity. (Kamal, A.; Ramesh, G.; Laxman, N.; Ramulu, P.; Srinivas, O.; Neelima, K.; Kondapi, A. K.; Srimu, V. B.; Nagarajaram, H. M. *J. Med. Chem.* 2002, 45, 4679).

Naturally occurring pyrrolo[2,1-c][1,4]benzodiazepines belong to a group of antitumour antibiotics derived from *Streptomyces* species. Recently, there is much impetus for the PBD systems as they can recognize and bind to specific sequence of DNA. Examples of naturally occurring PBD's include anthramycin, DC-81, tomaymycin, sibiromycin and neothramycin.

3

However, the clinical efficacy for these antibiotics is hindered by several limitations, such as poor water solubility, cardiotoxicity, development of drug resistance and metabolic inactivation.


OBJECTS OF THE INVENTION

The main object of the present invention is to provide new pyrrolo[2,1-c][1,4]-benzodiazepine hybrids useful as antitumour agents.


Another objective of the present invention is to provide a process for the preparation of novel pyrrolo[2,1-c][1,4]-benzodiazepine hybrids useful as antitumour agents.

SUMMARY OF THE INVENTION

Accordingly the present invention provides novel pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula IV or VII wherein R=H, OH and n is 2-3.





Formula IV



n = 2-3
R = H, OH

Formula VII



n = 2-3
R = H, OH

In one embodiment of the invention, the compound of the invention is selected from the group consisting of 7-Methoxy-8-[2'-(4"-acridonylcarboxamido)ethyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-Methoxy-8-[2'-(4"-acridonylcarboxamido)ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-Methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-Methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-Methoxy-8-[2'-(4"-acridonylcarboxamido)ethyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-


4

pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-Methoxy-8-[2'-(4"-acridonylcarboxamido)ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; 7-methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-Methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one.


The present invention also provides a process for preparation of pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula IV and VII wherein R=H, OH and n is 2-3,

15

Formula IV



20




25


15
n = 2-3
R = H, OH

Formula VII

30



35



40


25

45

the process comprising reacting an acridone or an acridine acid with (2S)-N-[4-(n'-aminoalkoxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I

50

Formula I




55

in the presence of EDCI and HOBt in organic solvent for a period of 24 h to obtain (2S)-N-[4-[n'-(4"-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal II/(2S)-N-[4-[n'-(4"-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula V where 'n' is 2-3,

60


65

5




II

Formula II



Formula V

isolating the compound of formula II/formula V and then reducing the compounds of formula II/formula V with $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ in presence of an organic solvent up to a reflux temperature, isolating the (2S)-N-{4-[n'-(4"-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolid-dine-2-carboxaldehydediethylthioacetal of formula III/(2S)-N-{4-[n'-(4"-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula VI where n is 2-3 by known methods,




III

Formula III

6

-continued



VI

Formula VI

reacting compound of formula III/formula VI with a known deprotecting agents in a conventional manner to give novel pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula IV/formula VII wherein n and R are as stated above.

In one embodiment of the invention, the organic solvent used for the reaction of the acridone/acridine acid with compound of formula I comprises dimethyl furan.

In another embodiment of the invention, the compound of formula II/formula V is isolated by washing with saturated NaHCO_3 , brine, drying and evaporation of the solvent.

In another embodiment of the invention the organic solvent used during the reduction of compound of formula II/formula V comprises methanol.


In a further embodiment of the invention, the compound of formula III/formula V is isolated by adjusting the pH of the reaction mixture to about pH 8 with a saturated NaHCO_3 solution, diluting with ethyl acetate, filtering through celite and extracted an organic phase and drying the organic phase over Na_2SO_4 .

In another embodiment of the invention, the deprotecting agent used for obtaining the compound of formula IV/formula VII comprises HgCl_2 and CaCO_3 in MeCN-water (4:1).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula IV or VII wherein $\text{R}=\text{H}$, OH and n is 2-3 and also provides a process for the preparation thereof.

The process of the invention comprises reacting an acridone or an acridine acid with (2S)-N-[4-(n'-aminoalkoxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I




Formula I


65

7


in the presence of EDCI and HOBT in organic solvent for a period of 24 h to obtain (2S)-N-{4-[n'-(4''-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II/(2S)-N-{4-[n'-(4''-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula V where n is 2-3,



Formula II




The compound of formula II/formula V is isolated and then reduced with $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ in the presence of an organic solvent such as methanol up to a reflux temperature to obtain (2S)-N-{4-[n'-(4''-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula III/(2S)-N-{4-[n'-(4''-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula VI where n is 2-3. The compounds of formula III/formula VI are then isolated by conventional methods.



Formula III



8

-continued



Formula VI

The compounds of formula III/formula VI with a known deprotecting agents in a conventional manner to give novel pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula IV/formula VII wherein n and R are as stated above



The organic solvent used for the reaction of the acridone/acridine acid with compound of formula I comprises dimethyl furan and the compound of formula II/formula V is isolated by washing with saturated NaHCO_3 , brine, drying and evaporation of the solvent. The organic solvent used during the reduction of compound of formula II/formula V comprises methanol and the compound of formula III/formula VI is isolated by adjusting the pH of the reaction mixture to about pH 8 with a saturated NaHCO_3 solution,

diluting with ethyl acetate, filtering through celite and extracted an organic phase and drying the organic phase over Na_2SO_4 .

The deprotecting agent used for obtaining the compound of formula IV/formula VII comprises HgCl_2 and CaCO_3 in MeCN-water (4:1).

The precursors, acridone acid (Atwell, G. J.; Cain, B. F.; Baguley, B. C.; Finlay, G. J.; Denny, W. A. *J. Med. Chem.* 1984, 27, 1481), acridine acid (Atwell G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. *J. Med. Chem.* 1987, 30, 664) and (2S)-N-[4-(n[□]-aminoalkoxy)-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (Thurston, D. E.; Morris, S. J.; Hartley, J. A. *Chem. Commun.* 1996, 563–565) have been prepared by literature methods.

Some representative compounds of formula IV/VII present invention are given below


1. 7-Methoxy-8-[2'-(4''-acridonylcarboxamido)ethyl]-oxy-(11aS)1,2,3,11a-tetra-hydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
2. 7-Methoxy-8-[2'-(4''-acridonylcarboxamido)ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
3. 7-Methoxy-8-[3'-(4''-acridonylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetra-hydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
4. 7-Methoxy-8-[3'-(4''-acridonylcarboxamido)propyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
5. 7-Methoxy-8-[2'-(4''-acridinylcarboxamido)ethyl]-oxy-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
6. 7-Methoxy-8-[2'-(4''-acridinylcarboxamido)ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3-11a-tetrahydro-5-H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
7. 7-Methoxy-8-[3'-(4''-acridinylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetra-hydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
8. 7-Methoxy-8-[3'-(4''-acridinylcarboxamido)propyl]-oxy-(4R)-hydroxy-(11aS)1,2,-3,11a tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one

These new analogues of pyrrolo[2,1-c][1,4]benzodiazepine hybrids linked at C-8 position have shown promising DNA binding activity and efficient anticancer activity in various cell lines. The molecules synthesized are of immense biological significance with potential sequence selective DNA-binding property. This resulted in design and synthesis of new congeners as illustrated in Scheme-1/ Scheme-2, which comprise:


1. The ether linkage at C-8 position of DC-81 intermediates with acridone/acridine ring moiety.
2. Up to refluxing the reaction mixture for 12–48 h.
3. Synthesis of C-8 linked PBD antitumour antibiotic hybrid imines.
4. Purification by column chromatography using different solvents like ethyl acetate, hexane, dichloromethane and methanol.

The reaction schemes are given below and are representative of the process of the invention.

Scheme 1



Scheme 2



$n = 2-3$
 $R = \text{H}, \text{OH}$

The following examples are given by way of illustration and therefore should not be construed to the present limit of the scope of invention.

Compound acridone acid (0.239 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (2S)-N-[4-(2'-aminoethyl)ox-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.443 g, 1 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silicagel using ethylacetate/hexane (8:2) solvent to give compound (2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

The compound (2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.664 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.0634 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[2'-(4''-acridonylcarboxamido)ethyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one.

EXAMPLE 2

Compound acridone acid (0.239 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (4R)-hydroxy-(2S)-N-[4-(2'-aminoethyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethylthioacetal of formula I (0.459 g, 1 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethyl acetate/hexane (8:2) solvent to give (4R)-hydroxy-(2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

The compound (4R)-hydroxy-(2S)-N-{4-[2'-(4''-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioac-

13

etal II (0.680 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}-pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridonylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.650 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[2'-(4"-acridonylcarboxamido)-ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepin-5-one.

EXAMPLE 3

Compound acridone acid (0.239 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (2S)-N-[4-(3'-aminopropyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.457 g, 1 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethylacetate/hexane (8:2) solvent to give compound (2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

¹H NMR (CDCl₃) δ 1.20–1.50 (m, 6H), 1.60–2.20 (m, 6H), 2.60–2.80 (m, 4H), 3.10–3.3 (m, 2H), 3.65–3.8 (m, 5H), 4.20–4.30 (m, 2H), 4.55–4.70 (m, 1H), 4.8 (d, 1H), 6.75 (s, 1H), 7.15 (t, 1H), 7.25 (t, 1H), 7.35 (d, 1H), 7.50 (s, 1H), 7.58–7.63 (t, 1H), 7.9 (bs, 1H), 8.15 (d, 1H), 8.35 (d, 1H), 8.55 (d, 1H); 12.3 (bs, 1H), MS (FAB) 679 [M+H]⁺.

The compound (2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.678 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was complete. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethylacetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford crude (2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

¹H NMR (CDCl₃) δ 1.20–1.45 (m, 6H), 1.55–2.35 (m, 6H), 2.60–2.85 (m, 6H), 3.6 (s, 3H), 3.7–3.8 (m, 2H), 4.15–4.25 (m 2H), 4.62–4.75 (m, 2H), 6.25 (s, 1H), 6.8 (s,

14

1H), 7.15–7.3 (m, 2H), 7.35 (d, 1H), 7.65–7.70 (t, 1H), 7.85 (br, 1H), 8.05 (d, 1H), 8.35 (d, 1H), 8.65 (d, 1H); 12.3 (bs, 1H).

A solution of compound (2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.648 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepin-5-one.

¹H NMR (CDCl₃) δ 1.20–1.30 (m, 2H), 1.85–2.40 (m, 6H), 3.5–3.8 (m, 6H), 4.20–4.30 (m, 2H), 6.80 (s, 1H), 7.2–7.35 (m, 2H) 7.40 (d, 1H), 7.5 (s, 1H), 7.65 (d, 1H), 7.75 (t, 1H), 8.05 (d, 1H), 8.45 (d, 1H), 8.65 (d, 1H); 12.25 (bs, 1H), MS (FAB) 525 [M+H]⁺.

EXAMPLE 4

Compound acridone acid (0.239 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (4R)-hydroxy-(2S)-N-[4-(3'-aminopropyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.473 g, 5 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethyl acetate/hexane (8:2) solvent to give (4R)-hydroxy-(2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

The compound (4R)-hydroxy-(2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.694 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (4R)-hydroxy-(2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (4R)-hydroxy-(2S)-N-{4-[3'-(4"-acridonylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.664 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was

15

evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[3'-(4"-acridonylcarboxamido) propyl]-oxy-(4R)-hydroxy-(11aS) 1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepin-5-one.

EXAMPLE 5

Compound acridine acid (0.223 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (2S)-N-[4-(2'-aminoethyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.443 g, 1 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethyl acetate/hexane (8:2) solvent to give compound (2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

The compound (2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}-pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.648 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.618 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[2'-(4"-acridinylcarboxamido)ethyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one.

EXAMPLE 6

Compound acridine acid (0.223 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (4R)-hydroxy-(2S)-N-[4-(2'-aminoethyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxyldehyde diethyl thioacetal for formula I (0.459 g, 1 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethyl acetate/hexane (8:2) solvent to give (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

16

The compound (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.664 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (4R)-hydroxy-(2S)-N-{4-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.634 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[2'-(4"-acridinylcarboxamido)-ethyl]-oxy-(4R)-hydroxy-(11aS)1,2,3-11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepin-5-one.

EXAMPLE 7

Compound acridine acid (0.223 g, 1 mmol) was taken in dry DMF (10 mL), EDCI (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (2S)-N-[4-(3'-amino-propyl)oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.457 g, 1 mmol) in DMF was added to it at same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethylacetate/hexane (8:2) solvent to give (2S)-N-{4-[2'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

¹H NMR (CDCl₃) δ 1.20–1.50 (m, 6H), 1.60–2.40 (m, 6H), 2.60–2.85 (m, 4H), 3.10–3.25 (m, 2H), 3.85–3.9 (m, 5H), 4.20–4.30 (m, 2H), 4.65–4.70 (m, 1H), 4.82 (d, 1H), 6.8(s, 1H), 7.4–7.8 (m, 4H), 7.85–8.05 (t, 2H), 8.10 (d, 1H), 8.82 (s, 1H), 11.9(bs, 1H), MS (FAB) 663 [M+H]⁺.

The compound (2S)-N-{4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.662 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (2S)-N-{4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

17

¹H NMR (CDCl₃) δ 1.20–1.5 (m, 6H), 1.60–2.40 (m, 6H), 2.60–2.80 (m, 4H), 3.55–3.7 (m, 2H), 3.8 (s, 3H), 3.9–4.00 (m, 2H), 4.15–4.25 (m, 2H), 4.65–4.80 (m, 2H), 6.25 (s, 1H), 6.8 (s, 1H), 7.50–7.80 (m, 4H), 7.90–8.00 (m, 2H), 8.85 (s, 1H), 8.95 (d, 1H), 11.9 (bs, 1H).

A solution of compound (2S)-N-{4-[3-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.632 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through celite bed. The clear yellow organic supernatant was extracted with saturated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[3'-(4"-acridinylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo [2,1-c][1,4]benzodiazepin-5-one.

¹H NMR (CDCl₃) δ 1.20–1.30 (m, 2H), 1.95–2.45 (m, 6H), 3.5–3.8 (m, 5H), 4.25–4.45 (m, 3H), 6.80 (s, 1H), 7.50–7.80 (m, 5H), 7.95–8.1 (m, 2H), 8.15 (d, 1H), 8.90 (s, 1H), 9.00 (d, 1H); 12.00 (bs, 1H), MS (FAB) 509 [M+H]⁺.

EXAMPLE 8

Compound acridine acid (0.223 g, 1 mmol) was taken in dry DMF (10 mL), (0.203 g, 1.5 mmol) and HOBt (0.288 g, 1.5 mmol) was added and the mixture was cooled at 0–5° C. and the mixture was stirred for 30 min. A solution of (4R)-hydroxy-(2S)-N-[4-(3'-aminopropyl)-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I (0.473 g, 5 mmol) in DMF was added to it at the same temperature and the solution was stirred at room temperature for overnight. The mixture was washed with saturated NaHCO₃ (50 mL), brine, dried and solvent was evaporated. The crude material was chromatographed over silica gel using ethyl acetate/hexane (8:2) solvent to give compound (4R)-hydroxy-(2S)-N-[4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal II as a yellow liquid.

The compound (4R)-hydroxy-(2S)-N-[4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal II (0.678 g, 1 mmol) was dissolved in methanol (15 mL) and added SnCl₂·2H₂O (1.128 g, 5 mmol) was refluxed for 2 h or until the TLC indicated that reaction was completed. The reaction mixture was then adjusted to pH 8 carefully with saturated NaHCO₃ solution, diluted with ethyl acetate, filtered through celite and extracted. The combined organic phase was dried over Na₂SO₄, and evaporated under vacuum to afford the crude compound (4R)-hydroxy-(2S)-N-[4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal III.

A solution of compound (4R)-hydroxy-(2S)-N-[4-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-5-methoxy-2-aminobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal III (0.648 g, 1 mmol), HgCl₂ (0.8145 g, 3 mmol) and CaCO₃ (0.3 g, 3 mmol) in MeCN-water (4:1) was stirred slowly at room temperature until TLC indicates complete loss of starting material. The reaction mixture was diluted with EtOAc (30 mL) and filtered through a celite bed. The clear yellow organic supernatant was extracted with satu-

18

rated 5% NaHCO₃ (20 mL), brine (20 mL) and the combined organic phase is dried (Na₂SO₄). The organic layer was evaporated in vacuum and purified by column chromatography (90% CH₂Cl₂-MeOH) to give compound 7-methoxy-8-[3'-(4"-acridinyl carboxamido) propyl]-oxy-(4R)-hydroxy-(11aS) 1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c]-[1,4]-benzodia-zepin-5-one.

Biological Activity: In vitro biological activity studies were carried out at National Cancer Institute (USA).

Cytotoxicity: 7-methoxy-8-[3'-(4"-acridinylcarboxamido)propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo [2,1-c][1,4]benzodiazepin-5-one of formula IV was evaluated for primary anti-cancer activity (Table 1) and in vitro against sixty human tumour cells derived from nine cancer types (leukemia, non-small-cell lung, colon, CNS, melanoma, ovarian, prostate, and breast cancer). For each compound, dose response curves for each cell line were measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug expose was used and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration causing 50% cell growth inhibition (GI50), total cell growth inhibition (TGI, 0% growth) and 50% cell death (LC50, -50% growth) compared with the control was calculated. The mean graph midpoint value s of log₁₀TGI and log₁₀LC50 as well as log₁₀ GI50 for IV are listed in Table 2. The mean graph itself is shown in Table 4. As demonstrated by mean graph pattern, compound IV exhibits an interesting profile of activity and selectivity for various cell lines. The mean graph mid point of log₁₀ TGI and log₁₀ LC50 showed similar pattern to the log₁₀ GI50 mean graph mid points.

TABLE 1

In vitro one dose primary anticancer assay ^a acridone linked PBD hybrid of IV			
PBD hybrid	Growth percentages		
	(Lung) NCI-H460	(Breast) MCF7	(CNS) SF-268
IV	0	0	10

^aOne dose of IV at 10⁻⁴ molar concentration

The novel pyrrolbenzodiazepine hybrid 7-methoxy-8-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one of formula IV has shown to possess <10 nano molar potency (at the LC₅₀ level) against one melanoma cancer (UACC-62) and 0.1 micro molar potency against colon cancer (HCC-2998), CNS cancer (SNB-75), breast cancer (MDA-MB-435) and also have >10 micro molar potency against two melanoma cancer cell lines (LOXIMVI, M14) and one renal cancer (SN12C). The LC₅₀ values of nine cancers (average of six to nine cancer cell lines) of compound 7-methoxy-8-[3'-(4"-acridinylcarboxamido)-propyl]-oxy-(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one of formula IV listed in Table 3.

19

TABLE 2

log₁₀ GI50 log₁₀ TGI and log₁₀ LC50 mean graphs midpoints(MG_MID) of in vitro cytotoxicity data for the compound IV against human tumour cell lines.

Compound	Log ₁₀ GI50	Log ₁₀ TGI	Log ₁₀ LC50
IV	-7.73	-5.56	-4.32

TABLE 3




Log LC50 (concentration in mol/L causing 50% lethality) Values for Compounds IV

Cancer	Compound IV
Leukemia	-4.00
non-small-cell lung	-4.14
Colon	-4.33
CNS	-4.425
Melanoma	-5.09
Ovarian	-4.012
Renal	-4.27
Prostate	-4.00
Breast	-4.40

Each cancer type represents the average of six to nine different cancer cell lines.


What is claimed is:

1. A compound of the formula given below wherein R is H or OH and n is 2 or 3




20


2. A compound as claimed in claim 1 of the structure




3. A compound as claimed in claim of the structure



4. A compound as claimed in claim 1 of the structure




5. A compound as claimed in claim 1 of the structure




21


6. A compound as claimed in claim 1 of the structure




7. A compound as claimed in claim 1 of the structure




8. A compound as claimed in claim 1 of the structure



9. A compound as claimed in claim 1 of the structure




10. A process for the preparation of a compound of the formula wherein R is H or OH and n is 2 or 3



22


-continued



20 the process comprising the steps of:


- a) reacting an acridone or an acridine acid with (2S)-N-[4-(n'-aminoalkoxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I

FORMULA I



40 in the presence of EDCI and HOBt in organic solvent for a period of 24 h to obtain (2S)-N-{4-[n'-(4''-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula II/(2S)-N-{4-[n'-(4''-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-


45 carboxaldehyde diethyl thioacetal of formula V where n is 2 or 3 and R is H or OH;



FORMULA II




23




FORMULA V

- b) isolating the compound of formula II/formula V, and
 c) then reducing the compounds of formula II/formula V with $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ in presence of an organic solvent up to a reflux temperature;
 d) isolating the (2S)-N-{4-[n'-(4''-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehydediethylthioacetal of formula III/(2S*)-N-{4-[n'-(4''-acridinylcarboxy-amido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula VI where n is 2 or 3 and R is H or OH;



FORMULA III






FORMULA VI

and

- e) reacting the compound of formula III/formula VI with a deprotecting agent to obtain the compound of formula

24



11. The process as claimed in claim 10 wherein the organic solvent used for the reaction of the acridone/acridine acid with the compound of formula I comprises dimethyl furan.


12. The process as claimed in claim 10 wherein the compound of formula II/formula V is isolated by washing with saturated NaHCO_3 , brine, drying and evaporating the solvent.

13. The process as claimed in claim 10 wherein the organic solvent used during the reduction of compound of formula II/formula V comprises methanol.

14. The process as claimed in claim 10 wherein the compound of formula III/formula V is isolated by adjusting the pH of the reaction mixture to about pH 8 with a saturated NaHCO_3 solution, diluting with ethyl acetate, filtering through celite and extracting an organic phase and drying the organic phase over Na_2SO_4 .



15. The process as claimed in claim 10 wherein the deprotecting agent used for obtaining the compound of formula IV/formula VII comprises HgCl_2 and CaCO_3 in MeCH-water (4:1).

16. The pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula given below wherein R is H or OH and n is 2 or 3 and a pharmaceutically acceptable additive.






25

-continued



17. A method for the treatment of cancer wherein the cancer is selected from the group consisting of leukemia, non-small cell, lung, colon, CNS, melanoma ovarian, renal, prostate and breast in a mammal suffering from the same comprising administering a pharmaceutically effective amount of a compound of the formula

26



wherein R is H or OH and n is 2-3 to the mammal.

30 18. A method as claimed in claim 17 wherein the mammal is a human being.

* * * * *